News Detail

my country's new pharmaceutical retail is ushering in a new opportunity for explosion

Issuing time:2021-08-30 14:33

According to relevant data, the total sales of my country's three major pharmaceutical retail terminals (public hospitals, retail pharmacies, and public primary medical care) in 2020 will reach 1,643.7 billion yuan, an increase of -8.5% year-on-year. Among them, the terminal sales of public hospitals were 1051.2 billion yuan, the terminal sales of retail pharmacies were 433 billion yuan, and the public primary medical terminal sales were 159.5 billion yuan.

   Affected by the epidemic, centralized procurement and key monitoring drug catalogues, in recent years, the terminal sales of public hospitals in my country have experienced negative growth for the first time, and the retail pharmacy terminal has been the least affected by the epidemic among the three terminals and recovered quickly.

   At the same time, the escalation of health needs and the outflow of prescriptions have contributed to the expansion of the pharmaceutical retail market, and changes in consumption habits and breakthroughs in geographical restrictions have promoted the redistribution of drug terminal traffic. Under the influence of the epidemic, the development of "Internet + medical health" accelerated, which accelerated the end of the traditional retail high-margin era and ushered in the new pharmaceutical retail era.

  The proportion of retail pharmacies has increased and the three models complement each other

The drug sales terminals in the pharmaceutical market in my country can be divided into three major terminals and six major markets, namely, public hospital terminals (urban public hospitals and county-level public hospitals), retail pharmacies terminals (physical pharmacies and online pharmacies), and public primary medical terminals (urban communities). Health centers and township health centers).

The proportion of retail pharmacies has gradually expanded since 2015. In 2020, the sales of the three major drug retail terminals will be 1,643.7 billion yuan. Although public hospitals still occupy an absolute share of 64.0%, the proportion of retail pharmacies and primary medical institutions has increased over the past five years. Gradually increasing, the proportion of retail pharmacies has increased from 23.3% in 2013 to 26.3% in 2020. In the first half of 2020, due to the impact of the new crown pneumonia epidemic, demand at hospitals has shrunk, and demand at pharmacies has further increased.

   In 2020, my country's pharmaceutical e-commerce market will reach 195.6 billion yuan, a year-on-year increase of 28.3%, accounting for 11.4% of my country's total pharmaceutical market. The pharmaceutical e-commerce business model is gradually improving. The three business models of B2B (business to business), B2C (business to individual), and O2O (online to offline) complement each other.

   B2B is good for upstream and downstream industries. The epidemic has caused the traditional offline mode of pharmaceutical circulation to face multiple challenges such as insufficient supply, slow information, and restricted traffic. The B2B platform has begun to emerge as a "bridge" linking the upstream supply chain and downstream terminals.

Under the epidemic, the medical e-commerce B2C broke out against the trend. The medical B2C model became the mainstream way of purchasing drugs. Because of its rich types of drugs, convenient online diagnosis and treatment, and the availability of drugs in sinking areas, it better met social needs and created To a greater social value.

  The epidemic has spurred O2O in medicine, and pharmacies and pharmaceutical companies have deployed one after another. With the gradual improvement of the online payment system, the epidemic has catalyzed the penetration rate of offline contactless distribution models to increase significantly, and O2O in medicine has ushered in a period of accelerated development. Traditional chain pharmacies expand their O2O business layout, single pharmacies expand their service radius through O2O, and Internet drug distribution platforms have successively launched investment and financing plans.

  Policy promotes industry changes and rapid development of online medical care

  Policy promotion is the main cause of changes in industry formats. In recent years, in order to increase the concentration of the pharmaceutical retail industry, standardize the development of the industry, and promote the outflow of prescriptions, government departments have issued a series of policies on licensed pharmacists, prescription outflows, volume procurement, and pharmacy classification management.

Among them, policies such as the two-invoice system, mass procurement, and medical insurance reform have continued to be implemented, raising the industry threshold and increasing industry concentration; the implementation of the pharmacy classification management system, the establishment of an electronic prescription circulation platform, the Internet online diagnosis and treatment and prescribing policies The gradual improvement and the continuous refinement of supporting policies for licensed pharmacists will support the outflow of prescriptions from all dimensions.

   In 2020, my country's online medical market will reach 19.6 billion yuan, and it is expected to grow to 105.8 billion yuan by 2025. During the epidemic, the advantages of online diagnosis and treatment platforms were outstanding, which deepened the general public's understanding of online medical care, increased public recognition of online consultations, and promoted the construction of the field of online diagnosis and treatment. Internet medical treatment is a new application of the Internet in the medical industry, including health education, medical information inquiry, electronic health records, disease risk assessment, online disease consultation, electronic prescriptions, remote consultation, and remote treatment and rehabilitation using the Internet as a carrier and technical means. Various forms of health and medical services.

   DTP has become a "competitive place" for all enterprises to build a new pattern of pharmaceutical retail

DTP (Direct to Patient) pharmacy refers to a drug manufacturer that does not use commercial agents or government drug bidding and purchase links, and directly authorizes the product to the drug store. After the patient obtains a prescription in the hospital, the drug can be purchased directly from the drug store and receive medication guidance and services. model. In order to seize the market opportunity of prescription outflow, major retail companies are actively deploying DTP professional pharmacies. By the end of 2020, Yifeng Pharmacy has more than 40 DTP pharmacies, Dashenlin Pharmaceutical Group has 89, ordinary pharmacies 143, and Sinopharm has more than 100 DTP pharmacies.

   From 2018 to 2020, Yifeng Pharmacy's DTP business varieties have increased from nearly 200 to nearly 400, and the DTP business varieties of ordinary people's pharmacies have increased from 343 to 635, and the expansion rate is very fast. Different from traditional retail pharmacies that mainly sell OTC drugs, DTP pharmacies mainly sell high-margin specialty drugs, new specialty drugs, self-paid drugs, etc., and are equipped with licensed pharmacists to provide professional medication guidance and services. It is an advanced model of retail pharmacies ( (See picture).

   With the support of the policy, the outflow of prescriptions has also taken the fast lane. Prescription outflow refers to hospitals opening prescriptions to the outside world, and patients can purchase prescription drugs at retail pharmacies by virtue of the prescriptions.

   Over the years, policies related to prescription outflow have been continuously promoted, and the policies have focused on three major directions: expressly prohibiting and restricting prescription outflow, regulating retail pharmacies, and encouraging electronic prescriptions. In 2020, the scale of my country's public hospital drug market is 1051.2 billion yuan. It is expected that the public hospital drug market will grow at a growth rate of 2% in the future.

   At present, Internet giants, pharmaceutical companies, and traditional retail pharmacies have frequent new pharmaceutical retail actions. JD Health is a large-scale online pharmaceutical retail platform in China. It has 11 drug warehouses across the country, and its channel network covers more than 200 cities across the country. Its sales scale is expanding rapidly; The business cooperation of "health" company explores and builds the online industry chain model of "Internet + medicine + medicine"; Yifeng Pharmacy established Hainan Yifeng Internet Hospital Co., Ltd. and Hainan Yifeng Telemedicine Center Co., Ltd. to create online + An omni-channel and omni-directional service system for offline, general + specialist family doctors and home pharmacists.

   The epidemic has accelerated the public’s awareness of online consultations, Internet hospitals, and online pharmacies. With the development of cloud computing, big data and AI technologies, the country has successively issued a number of favorable policies, and pharmaceutical retail companies will have stronger expansion power and broader development space in the era of "Internet + medical health" development. (Contributed by Head Leopard Research Institute)

Share to:
Add:Room 3-21401, Wangting International, No. 80 Gaoxin Road, High-tech Zone, Xi'an
HOME            SUPPORT           PRODUCTS            ABOUT US           NEWS